Resistance to endocrine therapy in breast cancer is common. With the aim of discovering new molecular targets for breast cancer therapy, we have recently identified LMTK3 as a regulator of the estrogen receptor-alpha (ERa) and wished to understand its role in endocrine resistance. We find that inhibition of LMTK3 in a xenograft tamoxifen (Tam)-resistant (BT474) breast cancer mouse model results in re-sensitization to Tam as demonstrated by a reduction in tumor volume. A whole genome microarray analysis, using a BT474 cell line, reveals genes significantly modulated (positively or negatively) after LMTK3 silencing, including some that are known to be implicated in Tam resistance, notably c-MYC, HSPB8 and SIAH2. We show that LMTK3 is able to increase the levels of HSPB8 at a transcriptional and translational level thereby protecting MCF7 cells from Tam-induced cell death, by reducing autophagy. Finally, high LMTK3 levels at baseline in tumors are predictive for endocrine resistance; therapy does not lead to alteration in levels, whereas in patient's plasma samples, acquired LMTK3 gene amplification (copy number variation) was associated with relapse while receiving Tam. In aggregate, these data support a role for LMTK3 in both innate (intrinsic) and acquired (adaptive) endocrine resistance in breast cancer.
INTRODUCTION
With an annual incidence of 1.3 million cases worldwide and 465,000 deaths, breast cancer remains the most frequently diagnosed type of cancer and the leading cause of cancer mortality in females.
1 Because ERa is expressed in over 70% of breast cancers, it is not surprising that many treatments thus far have focused on targeting ERa, directly or indirectly, by inhibiting its activity, stability and/or biosynthesis. [2] [3] [4] [5] Nevertheless, many patients become resistant to these treatments and relapse at a rate of 1-1.5% of those diagnosed per annum. Although mutations in the ERa are rarely found, 6 other mechanisms have been associated with tamoxifen (Tam) resistance, namely phosphorylation of ERa. 7 Thus, deciphering the role of kinases in modulating ERa activity may derive new druggable targets with the potential to reverse this resistance, including re-sensitizing cells to Tam. 8, 9 Using a high throughput screen with activity of estrogen-responsive genes as a quantitative read-out, we have recently identified Lemur Tyrosine Kinase 3 (LMTK3), for which a role had not previously been assigned, as a 'master' oncogenic regulator of ERa with transcriptional and translational effects. 10 To establish a role of LMTK3 in reversing endocrine resistance, we examined the effects of its inhibition in a Tam-resistant xenograft model and subsequent sensitivity to Tam. To understand the signaling pathways implicated, we performed a genome-wide gene expression analysis using the Tam-resistant cell line (BT474) with small interfering RNA (siRNA) knockdown of LMTK3, which revealed that LMTK3 is able to regulate the transcription of several genes, some of which have been previously described to have a role in ERa-positive breast cancer. We demonstrate that inhibition of LMTK3 decreased the total protein levels of HSBP8 (HSP22), a member of the heat-shock protein family, recently identified as a potential target for Tam resistance via a high-throughput ectopic expression screen. 11 Overexpression of LMTK3 promoted cell survival in MCF7 cells (Tam sensitive) after Tam treatment by reducing autophagy, suggesting a potential mechanism by which LMTK3 acts in the development on Tam resistance.
Resistance is typically innate (intrinsic) or acquired (adaptive), both factors that limit the success of therapies in the clinic. Whereas the latter is more common, we have previously shown in a large cohort that LMTK3 levels are predictive, as well as prognostic, in terms of response to Tam. Now, we have compared LMTK3 levels in responding breast cancers treated with endocrine therapy versus non-responding breast cancers during neoadjuvant treatment. 12, 13 Higher LMTK3 levels at baseline were associated with tumors that were less likely to respond to therapy.
We have recently used SNP6.0 arrays to profile the 'circulating cancer genome' comparing circulating free DNA (cfDNA) samples isolated from plasma with the primary tumor in 50 breast cancer patients during follow-up. Specific copy number variations (CNVs) were detected in cfDNA, mirroring the primary tumor, up to twelve years after diagnosis despite no other evidence of disease, suggesting dormancy in the majority of patients.
14 Because of the high density of probes, 906 600 for SNPs and 946 000 for CNVs, it is possible to interrogate SNP/CNV data for most genomic intervals. We therefore assayed CNV data in the LMTK3 gene in these patients and observed LMTK3 gene amplification in both cfDNA and primary tumor.
Together, these data implicate oncogenic activation of LMTK3 in a 'dual hit' model, promoting both tumor growth and as a route to intrinsic endocrine resistance.
RESULTS

Inhibition of LMTK3 re-sensitizes endocrine-resistant cells to Tam in vivo
Having already shown that knockdown of LMTK3 restores the Tam growth inhibitory effects in various Tam-resistant breast cancer cell lines, 10 we wished to investigate the involvement of LMTK3 in the development of endocrine resistance in vivo. Therefore, we used the BT474 cell line, 15 which expresses high endogenous LMTK3 messenger RNA (mRNA) and protein levels compared with other cell lines (Supplementary Figure 1) , to generate orthotopic breast cancer xenografts models. As expected, Tam-treated mice showed no changes in tumor volume compared with controls (P ¼ 0.63). Similar results were obtained when comparing control versus siLMTK3-treated mice (P ¼ 0.59). However, in the presence of both siLMTK3 and Tam, a significant inhibition of tumor growth was demonstrated compared with untreated controls (P ¼ 0.03), suggesting that inhibition of LMTK3 re-sensitizes cells to Tam in vivo (Figure 1 ), a numerically modest but statistically significant effect.
Inhibition of LMTK3 activates cellular pathways of endocrine responsiveness To identify signaling pathways relevant to endocrine responsiveness that LMTK3 may be implicated in, we performed a microarray-based genome-wide gene expression analysis using BT474 cells transfected with siControl or siLMTK3 in the presence or absence of different treatments (ETOH, E2 and E2 þ Tam), to simulate the treatment conditions used in the xenograft mouse model, recapitulating the physiological presence of E2 in female mice.
Initially, we identified genes that were significantly altered between any two groups defined by siRNA transfection (siCTRL, siLMTK3) and treatment (ETOH, E2, E2 þ Tam) by ANOVA analysis (BH-Q false discovery rate (FDR)o0.05). Principal component analyses using all genes from the ANOVA analysis showed that the strongest effects on expression level were induced by E2 treatment (Supplementary Figure 2) . We then constructed a heat map ranking genes according to degree of expression change upon E2 treatment. Figure 2a and Table 1 show the top 83 genes induced or repressed by E2 treatment. We found well-known E2 responsive genes such as PGR, GREB1, and TFF1 among the genes strongly induced by E2 in BT474 cells demonstrating that BT474 cells have retained functional ERa signaling. The observed E2 response was reversed to some degree by Tam treatment. However, for a limited number of genes (for example, OLFM1, MYBL1, GPR68, PDLIM3), a near-complete reversal of E2-induced expression change was observed (Supplementary Excel file 1). In contrast, depletion of LMTK3 had much stronger effects resulting in an almost completely abrogated E2 response over a wide range of genes (Figure 2b and Supplementary Excel file 2).
Among those genes, there were several that have been previously reported to be implicated in breast cancer progression, notably EGLN2 that regulates cyclin D1 and cell cycle progression in a hypoxia-inducible factor-dependent manner, 16 LAPTM4B that has a role in the development of de novo resistance to anthracycline-based chemotherapy, 17 RARA that is co-amplified in a subset of ERBB2 þ breast cancers, 18 UGT2B15 that reduces estrogen-mediated signaling in breast cancer cells, 19 and also those known to be relevant in the development of endocrine resistance (for example, c-myc, high protein levels of which are predictive of poor outcome following Tam therapy; 20, 21 HEY2, a direct target gene of the Notch signaling pathway, the activity of which is enhanced in endocrine resistant breast cancers; 22, 23 SIAH2, expression of which predicts disease-free survival in Tamtreated patients, 24 HSPB8 11 ), as well as genes that have not thus far been described as associated with breast cancer (for example, GPR68, a member of the family of ovarian cancer G-proteincoupled receptors that stimulate a variety of intracellular signaling pathways; 25, 26 and RASGRP1 that belong to the Ras guanyl nucleotide releasing proteins that may contribute to hematologic malignancies 27 ). Next, we searched for genes that are regulated by combined treatment with Tam and LMTK3 depletion, compared with siCTRLtreated cells, revealing various significantly downregulated and upregulated genes (Figure 2c and Supplementary Excel file 3). Finally, to identify genes that are relevant for re-sensitizing cells to Tam, we compared genes differentially regulated by the synergistic treatment of Tam and LMTK3 depletion to the effects of either of (Table 2 and Supplementary Excel file 4). Among those genes were some that have been implicated in various types of malignancies, including (i) MPPED2, previously linked to tumorigenesis in neuroblastoma; 28 (ii) FAM3B, which is relevant for pancreatic neuroendocrine tumors and is linked to glucose regulation; 29 (iii) FGD3, a guanine nucleotide exchange factor Chemokine (C-X3-C motif) ligand 1 P78423 NP_002987.1. CXCL12
Chemokine (C-X-C motif) ligand 12 P48061 NP_000600.1. CXCR7
Chemokine (C-X-C motif) receptor 7 P25106 NP_064707.1. DEGS1
Delta (4) LMTK3 is implicated in endocrine resistance J Stebbing et al for Cdc42, involved in cell migration; 30 (iv) ID1, expression of which is associated with more invasive features of cancer and with the epithelial-mesenchymal transition; 31 (v) ID4, which is associated with shorter recurrence-free survival and increased risk for lymphnode metastasis after loss of its expression in primary breast cancer; 32 (vi) INPP4B tumor suppressor protein that is frequently lost in primary human breast carcinomas and is associated with high clinical grade and tumor size; 33, 34 (vii) SGK3, which is linked to estrogen receptor both in breast cancer cell lines and in primary tumor samples, and it has been shown that its overexpression partially protects MCF-7 cells against apoptosis caused by anti-estrogens. 35, 36 Validation of microarray data To validate our microarray results, we performed RT-qPCR analysis on a large subset of differentially expressed genes (Figure 3a) , and were able to reproduce the inhibitory effects of LMTK3 silencing on their expression after E2 treatment. In addition, to further validate that LMTK3 is responsible for the observed results, we examined the relative mRNA levels of those genes after overexpressing a plasmid encoding for full-length LMTK3. As expected, overexpression of LMTK3 (Figure 3b ) had the opposite effects on the transcriptional levels of these genes, compared with siLMTK3, confirming the specificity of LMTK3.
LMTK3 increases HSPB8 protein levels and protects MCF7 cells from Tam-induced cell death by reducing autophagy One gene of note among those significantly modulated by LMTK3 was HSPB8, which has been recently described to have an important role in Tam resistance by inhibiting autophagy and cell death. 11 To determine whether LMTK3 is also able to affect HSPB8 at translational level, we silenced and overexpressed LMTK3 in the presence of various treatments and examined the protein expression of HSPB8. As previously described, E2 or Tam treatment increased HSPB8 protein levels; 37 however, this increase was abrogated after inhibition of LMTK3 (Figure 4a) . Further, ectopic expression of LMTK3 resulted in stabilization and further increase of HSPB8 protein levels, independently of treatments (Figure 4b ), demonstrating the effects of LMTK3 on HSPB8 translation.
As HSPB8 has been shown to support proliferation of Tamsensitive cell lines by inhibiting autophagy, we investigated the effects of LMTK3 overexpression on the survival of MCF7 cells in the presence and absence of Tam. Tam alone resulted in B70% cell death after 6 days of treatment, whereas overexpression of LMTK3 partly rescued cells from Tam-induced cell death (Figure 4c ), implying that LMTK3 is relevant for cellular survival.
To clarify whether LMTK3 is able to protect from cell death by blocking autophagy through increased HSPB8 protein levels, we examined the expression of MAPLC3, a well-known autophagosomal marker. Immunofluorescence of MCF7 cells revealed the characteristic punctuate pattern of MAPLC3 after Tam treatment, whereas ectopic expression of LMTK3 seems to decrease the number of autophagic cells (Figure 4d ). Taken together, these results suggest that LMTK3 can contribute to the development of Tam resistance via different signaling pathways including those implicated in autophagic processes.
LMTK3 cfDNA levels in plasma and breast tumors predict endocrine resistance In patients with ERa-positive breast tumors treated with aromatase inhibitors, LMTK3 levels determined by immunohistochemistry were higher in non-responders than responders determined by the changes of Ki67 labeling index changes 12, 13 at baseline (Po0.001) (Supplementary Figure 3 and Supplementary Table 1), but no significant changes were detected in LMTK3 levels before LMTK3 is implicated in endocrine resistance J Stebbing et al and after the therapy between responders and non-responders (Table 3 ). There was also no correlation between baseline LMTK3 and Ki67 levels (P ¼ 0.057). Furthermore, LMTK3 levels did not change significantly during treatment, supporting a role in innate resistance. Using copy number (CN) values of 42.5 and o1.5 as thresholds for amplification and deletion, respectively, there were no CN variations in the LMTK3 gene identified in any normal leukocyte DNA samples of the 50 patients on follow-up or in paired leukocytes and cfDNA of 8 healthy female controls. However, the 3'-(distal) end of the LMTK3 gene was amplified in 26% of primary tumor DNA samples and the entire gene was amplified in 10%. This tumor-specific amplification was detected in 64% of the first cfDNA samples and 68% of second cfDNA samples taken an average of 6 and 9 years after surgery and treatment (Supplementary Figure 4) , suggesting a role in acquired resistance. A small percentage of cfDNA samples (4% of first and 2% of second samples) also showed deletion at the 5 0 -end of the LMTK3 gene. Twenty five of the patients on follow-up received Tam and six of these patients went on to relapse. When results were compared, based on patients who relapsed compared with the patients who did not, significant CN gain (amplification) (Po0.0001) in both LMTK3 and ESR1 were detected specifically in the second cfDNA samples of the patients who relapsed again suggesting acquired resistance. These samples were taken just before relapse.
DISCUSSION
Endocrine resistance in breast cancer is frequent, resulting in significant mortality. Several studies thus far have revealed various signaling pathways implicated in this process but exact mechanisms require further elucidation, especially if we are to reverse this in the clinic. [38] [39] [40] [41] [42] Having recently identified LMTK3 as a novel regulator of ERa, we wished to examine its contribution in Tam re-sensitization. For this reason, we generated a Tam-resistant xenograft breast cancer mouse model, one we think that has broader utility as an endocrine-resistant model, and demonstrated that inhibition of LMTK3 expression is able to restore the inhibitory tumor growth effects of Tam. As this is the first time that LMTK3 has been linked to the development of resistance, we performed a human genome microarray analysis to identify target genes and signaling pathways affected by LMTK3 under different treatments (E2 and Tam). As expected, several of the newly identified LMTK3- Figure 3 . Effects of LMTK3 overexpression on the transcriptional levels of selected genes. BT474 cells were transfected with (a) siControl or siLMTK3 for 48 h, or (b) empty vector (pCMV6) or full-length LMTK3 (pCMV6-LMTK3) for 24 h, followed by treatment with ETOH (vehicle) or E2 (10 nM) for 24 h. The transcriptional levels of various genes (HSPB8, RARA, MYBL1, CXL12, IGFBP4, SIAH2, MYC and LMTK3) were analyzed by RT-qPCR (*Po0.05, **Po0.01, ***Po0.0001).
LMTK3 is implicated in endocrine resistance J Stebbing et al regulated genes have been previously linked to breast cancer development and also to Tam resistance, while others are new. Of note, the UGT2B15 and related UGT2B17 genes at 4q13.2 have been shown to be upregulated by E2 in MCF-7 cells 43 and may have a role in maintaining normal steroid hormone homeostasis and preventing excessive estrogen signaling. These genes also showed CNV in our SNP 6.0 study. 14 Among the genes whose expression was significantly reduced after inhibition of LMTK3 was HSPB8 (heat shock 22kDa protein 8), which is a member of the small heat-shock protein superfamily. 44 Although HSPB8 has been previously described to be an E2-regulated gene and its expression to be upregulated in breast cancer, 37, 45, 46 its potential involvement in Tam resistance was only recently described. 11 Overexpression of LMTK3 resulted in an increase of HSBP8 at both the mRNA and protein levels, suggesting a dual mechanism of action of LMTK3 on HSPB8 stability. Interestingly, ectopic expression of LMTK3 partly rescued proliferation of MCF7 cells (Tam-sensitive) by reducing autophagy, via increased HSPB8 levels. These data reveal LMTK3 as a new regulator of HSPB8 and propose a potential involvement of LMTK3 in the autophagic cell degradation process. However, taking into consideration the LMTK3-regulated gene-expression signature LMTK3 is implicated in endocrine resistance J Stebbing et al from our validated microarray, it is clear that further work will be required to establish LMTK3 interaction partners. There is very little questioning of the success of Tam and, despite meteoric rises in health-care costs for targeted therapies, Tam is a readily affordable drug that has saved millions of women 0 s lives. However, because not all ERa-positive breast cancers respond to Tam treatment, the development of methods to improve targeting Tam to treat the 'right' tumors would be of enormous value and LMTK3 as a biomarker has potential here. 47 Research has identified two forms of resistance to Tam therapy: intrinsic (de novo) resistance, when ERa-positive tumors do not respond to Tam at the outset of treatment which is uncommon, and acquired resistance, when ERa-positive tumors that initially respond to Tam subsequently exploit the Tam-ERa complexes as a stimulatory growth signal or, as we and others have shown, phosphorylation leads to ligand-independent activity. We have previously demonstrated in a very large European and a smaller Asian cohort that high baseline levels of LMTK3 are associated with more aggressive breast tumors, and that these are those patients more likely to relapse. 10, 47 As well as being a poor prognostic feature, LMTK3 levels were predictive, indicating a poorer response to Tam. We now show that these levels are generally unaltered throughout therapy, implicating LMTK3 in the less common form of 'unresponsiveness' to therapy, intrinsic resistance.
Plasma cfDNA analysis of breast cancer patients showed that many of them have specific CN changes in the LMTK3 gene detectable in cfDNA, which mirror those in their primary tumor, and that these persist over a number of years, despite the patient having received adjuvant therapy, and support a role for LMTK3 in intrinsic endocrine resistance. Furthermore, these data for LMTK3 support the genome-wide CN analysis, which revealed the persistence of tumor-associated CNVs in paired cfDNA samples years after surgery and treatment despite the fact that patients had no clinically evident recurrent disease.
14 However, of note, significant amplification (Po0.0001) of both ESR1 and LMTK3 genes detected in the cfDNA of six patients who relapsed while receiving Tam and may suggest one potential mechanism for development of acquired resistance to Tam (and endocrine therapy in general), although numbers here are low and should be prospectively validated. In the adjuvant setting, it could be that micrometastatic tumor cells are under selective pressure to harbor mutations that drive resistance to the therapy being applied and to later relapse. Amplifications in ESR1 and LMTK3 are two possible milestones on this path to relapse.
In aggregate, these data support the conclusion that LMTK3 is relevant in the development of endocrine resistance in breast cancer.
MATERIALS AND METHODS
Cell lines and arrays
MCF7 and BT474 were maintained in DMEM supplemented with 10% FCS (or 10% charcoal-dextran stripped serum) and 1% penicillin/streptomycin/ glutamine. All cells were incubated at 37 1C in humidified 5% CO 2 . Estradiol (E2) and Tam were obtained from Sigma and dissolved in 100% ethanol; charcoal-dextran stripped serum was obtained from Gemini (Northern California, CA, USA). The following antibodies were used: LMTK3 mouse monoclonal (Santa Cruz, Santa Cruz, CA, USA), MAPLC3 rabbit polyclonal (Cell Signaling, Danvers, MA, USA), HSPB8 rabbit polyclonal (Cell Signaling), FLAG mouse monoclonal (Cell Signaling), b-actin mouse monoclonal (Abcam, Cambridge, UK) The full-length human LMTK3 complementary DNA (cDNA) sequence (NM_001080434) was cloned in the eukaryotic expression vector pCMV6 (Myc/Flag tagged), using the SgfI and MluI restriction enzymes.
Xenograft model
We compared vehicle, LMTK3 siRNA, Tam, and a combination of LMTK3 siRNA and Tam in BT474 cells in immuno-compromised SCID mice (Harlan Laboratories, Indianapolis, IN, USA) between 7-8 weeks of age. BT474 cells were cultured in media containing FBS and injected into the mammary fat pad of mice at a concentration of 1 Â 10 7 cells/injection (Champions Biotechnology, Baltimore, MD, USA). Pre-study tumor volumes were recorded for the experiment. When tumors reached an approximate area of 100-200 mm 3 , animals (n ¼ 10) were randomly assigned to different groups and treated with i) 10 mg of control siRNA (in PBS), ii) 10 mg of LMTK3 siRNA, iii) 0.5 mg/kg of Tam þ 10 mg of control siRNA and, iv) 0.5 mg/kg of Tam þ 10 mg of LMTK3 siRNA); animals were tagged and followed individually throughout the experiment. Four intra-tumoral injections into mammary fat pad were repeated every 3 days and mice were terminated 3 days after the last injection. Tumor growth was monitored using calliper measurements. At termination, primary tumors were excised, weighed and formalin fixed. Statistical differences in tumor volume were determined using a two-tailed one-way (ANOVA) followed by the Dunnett's multiple comparisons test comparing treated single-agent groups (LMTK3 siRNA, or Tam) with control and combination (LMTK3 siRNA þ Tam) with standard agent (LMTK3 siRNA or Tam).
Illumina microarray hybridization siRNA: two different siRNAs (20 nM) for LMTK3 (LMTK3 siRNA 1 (targeting sequence: 5 0 -TGTCTGCGTAACCGCACGGG-3 0 ) and LMTK3 siRNA 2 (targeting sequence: 5'-GTTCATCTCGGAAGCACA-3' (Qiagen, Hilden, Germany). The All Stars Negative Control siRNA (Qiagen) (#1027280) was used as control. BT474 cells were transfected for 48 h with the LMTK3 siRNAs or control siRNA using Hiperfect followed by media change and treatment with E2 (10 nM) and/or Tam (100 nM) for 24 h. All siRNA transfections as well as all compound treatments were performed as three independent replicates. RNA was extracted with the RNeasy Mini Kit (Qiagen), followed by digestion of genomic DNA using the RNase-free DNase-Set (Qiagen). RNA concentration was measured on Nanodrop (Peqlab, Southampton, UK). RNA quality was determined on an Agilent Bioanalyzer. RNA Integrity Number for all total RNA samples was between 9.4-10 indicating excellent RNA quality. RNA labeling was performed on a Hamilton Star Roboter (Hamilton, Bonaduz, Switzerland) using the Illumina Total Prep-96 RNA Amplification kit from Ambion (Applied Biosystems, Carlsbad, CA, USA, #4393543). Briefly, from 500 ng total RNA first and second strand cDNA was synthesized, and cDNA was cleaned up using Agencourt magnetic beads CleanKit (#000494, Beckman Coulter, London, UK). After in vitro transcription, biotin-labeled cRNA was purified using Agencourt magnetic beads CleanKit. cRNA concentration was determined with Quant-iT RiboGreen (R-11490, Invitrogen). 1,5 mg CRNA was mixed with the hybridization reagents and hybridized to Illumina Human HT-12 v4 BeadChips. All washing and staining steps were performed with a Little Dipper Processor for Illumina BeadChips from Scigene (Sunnyvale, CA, USA). Biotin was detected with streptavidin-Cy3 (#PA43001, Amersham Biosciences, Piscataway, NJ, USA). The BeadChips were scanned on a Illumina Bead Array Reader (San Diego, CA, USA).
Bioinformatic analysis
BeadChip raw data output contains the average signal intensity and the detection P-value for each probe. Analyses were performed using GeneData's Expression Analyst (version 2.2.9). For quality control box plots of signal intensity, unsupervised hierarchical clustering and Principal Components Analysis for both un-normalized and median-normalized data were carried out without identifying any outliers. The analyses revealed even signal distribution within the set of experiments. A three-way ANOVA was used to investigate the influence of the factors 'cell lines', 'siRNA-', and 'compound-'treatment on differential gene expression (siRNA: control, mock and siLMTK3; compound: ETOH, E2, E2 þ Tam, E2 þ ICI). Most variability in gene expression could be explained by the factor cell line (data not shown) whereas both kinds of treatment had comparingly much smaller effects. Therefore, we investigated the effects of siRNA-and compound-treatment in each cell line separately using two-way ANOVA. Significantly differential gene expression between any two groups (as defined by the combination of siRNA and compound treatment) due to compound treatment was identified in a two-way ANOVA using BT474 cell line (factors: siRNA-and compound-treatment; effect: compound treatment, or siRNA treatment, or the interaction thereof).
The attached Excel table lists the 4718 genes showing significant changes in gene expression between any two groups (BH-Qo0.05) To look for synergistic effects, we calculated mean fold changes in expression of these genes due to Tam inhibition (siCTRL/E2 versus siCTRL/E2 þ Tam) or LMTK3 depletion (siCTRL/E2 versus siLMTK3/E2) or the combined effect LMTK3 is implicated in endocrine resistance J Stebbing et al (siCTRL/E2 versus siLMTK3/E2 þ Tam). Synergistic effects were defined according to the following formula: fc(siCTRL/E2 versus siLMTK3/E2 þ Tam)4fc(siCTRL/E2 versus siCTRL/E2 þ Tam) *fc(siCTRL/E2 versus siLMTK3/E2).
Quantitative RT-PCR (RT-qPCR)
Reverse transcription was performed using high-capacity cDNA reverse transcription kit (Applied Biosystems). RT-qPCR analysis was performed on a7900HT Thermocycler (Applied Biosystems) using QuantiTect SYBR Green PCR Kit and primers for HSPB8, RARA,MYBL1, CXCL12, IGFBP4, SIAH2, MYC, LMTK3 and GAPDH, purchased from Qiagen.
Cell proliferation assay
Cell proliferation was measured using the sulphorhodamine B growth assay, which is based on the measurement of cellular protein content. Briefly, B2500 cells were seeded in 96-well plates and after treatment, 100 ml of trichloroacetic acid were added to each well (cell fixation) and incubated for 1 h at 4 1C. Next, the plates were washed five times with double-distilled water (dd H 2 O) and stained at room temperature for 30 min with 0.4% sulphorhodamine B in 1% acetic acid. Finally, the plates were washed with 1% acetic acid solution and air dried overnight. Tris base (10 mmol/l) was added to the wells to solubilize the bound sulphorhodamine B dye. The absorbance was read at 492 nm using the Anthos 2001 microplate reader (Jencons Scientific Ltd, Leicestershire, UK).
Immunofluorescence and immunohistochemistry
Immunofluorescence experiments were carried out as described previously 10 using an Axiovert-200 laser scanning inverted microscope (Zeiss, Cambridge, UK) equipped with a confocal imaging system. Photoshop 8.0 (Adobe Software, San Jose, CA, USA) was used for post-acquisition editing of images.
Immunohistochemistry analysis of mice breast tissue sections for LMTK3, and Ki67 expression was performed as previously described. 47 High-resolution digital imaging (NanoZoomer, Hamamatsu Photonics, Bridgewater, NJ, USA) at 20x magnification with a web-based interface (Distiller, SlidePath Ltd, Dublin, Ireland) was used.
Patients
Twenty patients with ERa-positive primary breast cancer patients were treated with steroidal aromatase inhibitor, exemestane (10 cases) and nonsteroidal aromatase inhibitor, letrozole, for 24 weeks before the surgery as neoadjuvant study. 12, 13 Details of the clinical and pathological findings of the patients as well as the protocols of neoadjuvant clinical trial were previously described. 12, 13 Tumors were then stained before and after the treatment for LMTK3 as described previously, 47 and results were correlated with the clinical response and Ki67 response. The t-test was used for comparing changes in LMTK3 between groups.
We also analyzed DNA samples (leukocytes, tumor and paired cfDNA) from 50 patients described in our recent study.
14 Briefly, they were hybridized on GeneChip Human Mapping SNP 6.0 arrays, using the Human mapping SNP 6.0 assay kit following the Genome-Wide Human SNP Nsp/Sty 6.0 protocol (Affymetrix, Santa Clara, CA, USA) as described previously.
14 Data analysis was performed using Partek Genomics Suite 6.5, copyright 2010, build 6.10.1129 (Partek Inc, St Louis, MO, USA).
